Source: International Congress 2017 – The latest in lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
Anne-Marie Dingemans (Maastricht, Netherlands). Diagnostic-therapeutic sequences in advanced NSCLC: how to best standardise and personalise your strategies. International Congress 2017 – The latest in lung cancer

Member's Comments

No comment yet.

Related content which might interest you: Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the radiotherapist Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Eminence or evidence based ? – personalised diagnostic-therapeutic sequences in a molecular altered advanced NSCLC patient Source: International Congress 2017 – GR2 Lung Cancer Grand Round Year: 2017 Practical tools for implementing early palliative care in advanced lung cancer Source: Eur Respir J 2016; 47: 1010-1012 Year: 2016 New treatment concepts in stage IV NSCLC: personalized multidisciplinary approaches Source: Virtual Congress 2021 – Hot topics in thoracic oncology Year: 2021 Multimodal therapeutic approach for locally advanced NSCLC in everyday practice Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Modern staging in lung cancer: from the current multidisciplinary process to novel approaches Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Approaches in patients with locally advanced NSCLC: a surgeon's perspective Source: Eur Respir Monogr 2015; 68: 167-177 Year: 2015 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the (pneumo) oncologist Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the thoracic surgeon Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Poor performance status patient in advanced lung cancer: to treat or not to treat? Source: Annual Congress 2008 - MP13 - Poor performance status patient in advanced lung cancer: to treat or not to treat? Year: 2008 Patient-reported outcome measures: do they improve the quality of supportive care in advanced non-small cell lung cancer? Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? Source: Eur Respir J 2014; 44: 1011-1022 Year: 2014 Novel survey tool used to assess priorities of lung cancer patients and carers Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Approaches in patients with locally advanced NSCLC: a radiation oncologist's perspective Source: Eur Respir Monogr 2015; 68: 178-185 Year: 2015 Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times Source: Eur Respir J, 51 (6) 1800844; 10.1183/13993003.00844-2018 Year: 2018 Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times Source: Eur Respir J, 51 (6) 1800602; 10.1183/13993003.00602-2018 Year: 2018 The effectiveness of a multidisciplinary approach in the management of lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 495s Year: 2005 What specific issues arise in the management of elderly patients with advanced NSCLC? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007